Invesco QQQ Trust has submitted its Monthly Portfolio Investments Report to the SEC, detailing its financial status as of the month's end. The report shows total assets of approximately $288.64 billion, total liabilities of over $617 million, and net assets of around $288.02 billion. Cash and equivalents stand at $616.7 million. The Trust reported monthly total returns of -4.45%, 6.38%, and 6.27% over the last three months, with no derivatives gains or losses in the same period. Sales and redemptions of Fund shares were reported, but there was no change in the Highly Liquid Investment Minimum, nor significant exposure to derivatives transactions. The report also indicates that the Trust may not be subject to the leverage risk limit under rule 18f-4(c)(2) as no Value at Risk (VaR) information was provided. The detailed portfolio includes investments in major issuers such as Charter Communications, Coca-Cola Europacific Partners, and AstraZeneca, among others. The report adheres to U.S. GAAP (ASC 820) for fair value measurements and provides extensive details on debt securities, repurchase agreements, and securities lending.

Invesco QQQ Trust has submitted its Monthly Portfolio Investments Report to the SEC, detailing its financial status as of the month's end. The report shows total assets of approximately $288.64 billion, total liabilities of over $617 million, and net assets of around $288.02 billion. Cash and equivalents stand at $616.7 million. The Trust reported monthly total returns of -4.45%, 6.38%, and 6.27% over the last three months, with no derivatives gains or losses in the same period. Sales and redemptions of Fund shares were reported, but there was no change in the Highly Liquid Investment Minimum, nor significant exposure to derivatives transactions. The report also indicates that the Trust may not be subject to the leverage risk limit under rule 18f-4(c)(2) as no Value at Risk (VaR) information was provided. The detailed portfolio includes investments in major issuers such as Charter Communications, Coca-Cola Europacific Partners, and AstraZeneca, among others. The report adheres to U.S. GAAP (ASC 820) for fair value measurements and provides extensive details on debt securities, repurchase agreements, and securities lending.